Developmental mechanisms of CNS pathology in mitochondrial disease
Developmental mechanisms of CNS pathology in mitochondrial disease
批准号:
10468301
负责人:
Simon C Johnson
金额:
$47.13万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-15 至 2023-02-28
关键词:
AffectAgeAttenuatedBirthCaenorhabditis elegansCardiovascular DiseasesChildhoodClinicalComplexDataDefectDevelopmentDevelopmental BiologyDiseaseElectron TransportEnvironmental ExposureEtiologyEventFRAP1 geneFunctional disorderGeneticGoalsGrowthHealthHomologous GeneHumanHuman PathologyHypoxiaIndividualInterventionKnockout MiceLeadLeigh DiseaseLifeLinkMediatingMetabolicMetabolic DiseasesMetabolic dysfunctionMitochondriaMitochondrial DiseasesModelingMolecularMutationNematodaNeurodegenerative DisordersNeurologicNeurologic SymptomsOnset of illnessOrganPathogenesisPathologyPathway interactionsPhenotypePhysiologicalRoleSeizuresSirolimusSpecificitySymptomsSyndromeTestingTreatment EfficacyWorkacute symptomage relatedassociated symptomattenuationbaseexperimental studygene producthuman modelin uteroinsightketogenic dietmTOR InhibitormTOR inhibitionmitochondrial dysfunctionmouse modelneurodevelopmentnovelpostnatalpostnatal developmentpostnatal periodpreclinical studypreventtherapy developmenttrait
中文摘要
项目摘要/摘要
我们的长期目标是确定分子和细胞机制参与发病机制和
线粒体功能障碍的复杂临床表现。我们在研究中的整体目标是
这里,是追求这一目标的下一步,是定义发展和发病之间的关系
由线粒体电子传递链复合体I(ETC CI)功能障碍引起的疾病。我们
基于大量初步数据的假设,线粒体的一些主要神经后遗症
疾病是由线粒体功能和特定事件之间的相互作用机制驱动的
后天发育。特别是,我们的初步数据显示了疾病发病年龄的显著特异性。
而且,更能说明问题的是,在特定的产后期进行治疗对于持久是必要的,也是充分的。
受益于雷帕霉素治疗,这是一种在线粒体疾病的临床前研究中得到充分验证的干预措施。
我们的实验将利用Ndufs4(KO)小鼠,这是线粒体疾病的主要模型
看起来像人类的LS。此外,我们还生成了一种新的LS线虫模型,该模型具有较强的鲁棒性
发育表型,在线虫Ndufs4,LPD-5的同源物中是缺陷的。我们将使用这些
确定出生后神经发育在线粒体神经学特征发生中的作用的模型
疾病一)探讨疾病的主要神经后遗症的发生和发展之间的相互作用;二)
确定针对疾病的干预措施发展的关键窗口;三)确定遗传因素
参与线虫线粒体功能障碍相关的发育停滞。最终,这项工作
将促进我们对线粒体在发育生物学中的作用的理解,并有助于定义细胞
线粒体疾病的分子发病机制。
相关性
遗传性线粒体疾病涉及一系列症状,可影响一个器官或呈现为多系统
线粒体疾病具有显著的异质性,目前还没有被证实的治疗线粒体疾病的方法。
任何原因造成的。对个别线粒体疾病的发病机制有明确的认识是严重的
所需;复杂临床的分子、细胞、生理和发育机制
由原发遗传性线粒体功能障碍引起的综合征并不是不确定的。
英文摘要
Project Summary/Abstract
Our long-term goal is to define the molecular and cellular mechanisms involved in the pathogenesis and
complex clinical presentations of mitochondrial dysfunction. Our overall objective in the studies proposed
here, which are a next step in pursuing this goal, is to define the relationship between development and onset
of disease resulting from mitochondrial electron transport chain complex I (ETC CI) dysfunction. We
hypothesize, based on substantial preliminary data, that some of the major neurologic sequelae of mitochondrial
disease are mechanistically driven by the interaction between mitochondrial function and specific events in
postnatal development. In particular, our preliminary data reveal a striking specificity to age of disease onset
and, more telling, that treatment during a specific post-natal period is both necessary and sufficient for lasting
benefits from rapamycin treatment, a well-validated intervention in pre-clinical studies of mitochondrial disease.
Our experiments will take advantage of the Ndufs4(KO) mouse, apremier model of mitochondrial disease closely
resembling human LS. In addition, we have generated a novel nematode model of LS which has a robust
developmental phenotype and is defective in the C. elegans homologue of Ndufs4, lpd-5. We will use these
models to define the role of postnatal neurodevelopment in the onset of neurological features of mitochondrial
disease i) probe the interaction between development and onset of major neurological sequelae of disease ; ii)
define the critical window in development for interventions targeting disease; iii) identifying genetic factors
involved in developmental arrest associated with mitochondrial dysfunction in C. elegans. Ultimately, this work
will advance our understanding of the role of mitochondria in developmental biology and help define the cellular
and molecular pathogenesis of mitochondrial diseases.
Relevance
Genetic mitochondrial diseases involve an array of symptoms, can impact one organ or present as a multisystem
disorder, are remarkably heterogeneous, and currently there are no proven treatments for mitochondrial disease
of any etiology. A clear understanding of the pathogenesis of individual mitochondrial diseases is severely
needed; the molecular, cellular, physiological, and developmental mechanisms underlying the complex clinical
syndromes arising from primary genetic mitochondrial dysfunction have not been undefined.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s13023-022-02495-3
发表时间:
2022-09-02
期刊:
Orphanet journal of rare diseases
影响因子:
3.7
作者:
[]
通讯作者:
DOI:
10.1111/bpa.13192
发表时间:
2023-11
期刊:
Brain pathology (Zurich, Switzerland)
影响因子:
--
作者:
[]
通讯作者:
The role of astrocytes in emergence from volatile anesthetics
-
批准号:10340339
-
项目类别:
-
资助金额:$42.33万
-
财政年份:2022
-
负责人:Simon C Johnson
-
依托单位:
The role of astrocytes in emergence from volatile anesthetics
-
批准号:10776191
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2022
-
负责人:Simon C Johnson
-
依托单位:
Developmental mechanisms of CNS pathology in mitochondrial disease
-
批准号:10296147
-
项目类别:
-
资助金额:$47.13万
-
财政年份:2021
-
负责人:Simon C Johnson
-
依托单位:
The role of ketone metabolism in sequelae resulting from volatile anesthetic exposure.
-
批准号:10425335
-
项目类别:
-
资助金额:$37.2万
-
财政年份:2019
-
负责人:Simon C Johnson
-
依托单位:
The role of ketone metabolism in sequelae resulting from volatile anesthetic exposure.
-
批准号:10187595
-
项目类别:
-
资助金额:$37.2万
-
财政年份:2019
-
负责人:Simon C Johnson
-
依托单位:
The role of mTOR in mitochondrial encephalopathy
-
批准号:9920237
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2017
-
负责人:Simon C Johnson
-
依托单位:
Functional Characterization and Physiological Consequences of Human Longevity-Associated IGF1R Variants
-
批准号:9136482
-
项目类别:
-
资助金额:$5.42万
-
财政年份:2015
-
负责人:Simon C Johnson
-
依托单位:
Functional Characterization and Physiological Consequences of Human Longevity-Associated IGF1R Variants
-
批准号:9062284
-
项目类别:
-
资助金额:$1.26万
-
财政年份:2015
-
负责人:Simon C Johnson
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: